Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05406622 · ClinicalTrials.gov registry record · NA
MOTIV BTK Randomized Controlled Trial
A NA study of Critical Limb Ischemia, sponsored by REVA Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 292
- Enrollment target
- 4
- Study locations
NCT05406622: Recruiting NA study of Critical Limb Ischemia, sponsored by REVA Medical.
NCT05406622 is a NA study of Critical Limb Ischemia that is actively recruiting participants, run by REVA Medical. The registered enrollment target is 292 participants, above the 75-participant average among 18 other Critical Limb Ischemia trials with a reported enrollment target (289% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05406622, a NA study of Critical Limb Ischemia, is actively recruiting participants, sponsored by REVA Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 292 participants
- Enrollment target
- 4
- Study locations
Study Summary
Pre-market clinical evaluation of the MOTIV Sirolimus-Eluting Bioresorbable Scaffold for the planned treatment of infrapopliteal lesions.
Primary Outcome
Freedom from the composite of above-the-ankle amputation, target lesion occlusion, clinically driven target lesion revascularization (CD-TLR), and binary restenosis of the target lesion.
Conditions Studied
Interventions
- DEVICE MOTIV Sirolimus-Eluting Bioresorbable Scaffold
- DEVICE Percutaneous Transluminal Angioplasty (PTA) Device
Study Locations (4)
Iowa
- UnityPoint Health Trinity Bettendorf Hospital - Bettendorf
- Cardiovascular Medicine PC - Davenport
California
- Adventist Health - St. Helena
Other
- University Leipzig - Leipzig
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2022-06-10 |
| Est. Completion | 2029-03-31 |
| Phase | NA |
What NCT05406622 shows while recruiting
NCT05406622 is an interventional study that assigns participants to a tested intervention. The registered 292 participants enrollment target is mid-sized for trials with a published cap, above the 75-participant average among 18 other Critical Limb Ischemia trials with a reported enrollment target (289% higher).
The record links to 1 condition, with Critical Limb Ischemia appearing as the primary indexed condition, and to 2 interventions - of which MOTIV Sirolimus-Eluting Bioresorbable Scaffold is the first listed.
NCT05406622 reports a single indexed study location in Iowa, California, Other.
Frequently Asked Questions
What is clinical trial NCT05406622 about?
NCT05406622 is a clinical study titled "MOTIV BTK Randomized Controlled Trial". Pre-market clinical evaluation of the MOTIV Sirolimus-Eluting Bioresorbable Scaffold for the planned treatment of infrapopliteal lesions.
What is the current status of trial NCT05406622?
This trial is currently recruiting. It is a NA study. The enrollment target is 292 participants. The study started on 2022-06-10. Estimated completion is 2029-03-31.
What conditions does trial NCT05406622 study?
This clinical trial studies the following conditions: Critical Limb Ischemia.
What interventions are being tested in trial NCT05406622?
The interventions under investigation include: MOTIV Sirolimus-Eluting Bioresorbable Scaffold (DEVICE), Percutaneous Transluminal Angioplasty (PTA) Device (DEVICE).
Who is sponsoring clinical trial NCT05406622?
This trial is sponsored by REVA Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05406622 being conducted?
This trial has 4 study locations across California, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Critical Limb Ischemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05406622's enrollment target sits among peer trials
292 2nd of 18 the highest of 18 other Critical Limb Ischemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Critical Limb Ischemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
RECRUITING · NA
-
Serrantor OCT Study
RECRUITING · NA
-
Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries
COMPLETED · NA
-
A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)
COMPLETED · NA
-
BOLD MRI as a Surrogate of Improved Muscle Oxygenation Following Endovascular Therapy for the Treatment of CLI
COMPLETED · NA
-
PROMISE I Early Feasibility Trial of the LimFlow Stent Graft System
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- NCT05757102 · 292 participants · Phase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
- NCT06569667 · 292 participants · NA
Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
- NCT06724016 · 292 participants · Phase 1
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI